Human cysteine cathepsins are not reliable markers of infection by pseudomonas aeruginosa in cystic fibrosis

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Naudin, Clément ^a   Joulin Giet, Alix ^a   Couetdic, Gérard ^b   Plésiat, Patrick ^b   Szymanska, Aneta ^c   Gorna, Emilia ^c   Gauthier, Francis ^a   Kasprzykowski, Franciszek ^c   Lecaille, Fabien ^a   Lalmanach, Gilles ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c UNIVERSITY OF GDA SK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN; CATHEPSIN B; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CYSTATIN C; ENZYME INHIBITOR; KININOGEN; LEUKOCYTE ELASTASE; CYSTATIN; CYSTEINE; CYSTEINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; BACTERIAL COLONIZATION; CHEMICAL LABELING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME RELEASE; HUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSEUDOMONAS INFECTION; SPUTUM; CHEMISTRY; ENZYMOLOGY; KINETICS; METABOLISM; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS AERUGINOSA;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

BIOLOGICAL MARKERS; CATHEPSINS; CYSTATINS; CYSTEINE; CYSTEINE PROTEINASE INHIBITORS; CYSTIC FIBROSIS; HUMANS; KINETICS; KININOGENS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM;

EID: 80053293771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025577     Document Type: Article

References (44)

1. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, et al. (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073-1080.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, et al. (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
3. Grasemann H, Ratjen F, (2010) Emerging therapies for cystic fibrosis lung disease. Expert Opin Emerg Drugs 15: 653-659.
4. Pham CT, (2006) Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 6: 541-550.
5. Korkmaz B, Moreau T, Gauthier F, (2008) Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 90: 227-242.
6. Lalmanach G, Diot E, Godat E, Lecaille F, Herve-Grepinet V, (2006) Cysteine cathepsins and caspases in silicosis. Biol Chem 387: 863-870.
7. Lecaille F, Kaleta J, Bromme D, (2002) Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 102: 4459-4488.
8. Turk V, Turk B, Turk D, (2001) Lysosomal cysteine proteases: facts and opportunities. EMBO J 20: 4629-4633.
9. Buhling F, Waldburg N, Reisenauer A, Heimburg A, Golpon H, et al. (2004) Lysosomal cysteine proteases in the lung: role in protein processing and immunoregulation. Eur Respir J 23: 620-628.
10. Veillard F, Lecaille F, Lalmanach G, (2008) Lung cysteine cathepsins: intruders or unorthodox contributors to the kallikrein-kinin system? Int J Biochem Cell Biol 40: 1079-1094.
11. Takeyabu K, Betsuyaku T, Nishimura M, Yoshioka A, Tanino M, et al. (1998) Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur Respir J 12: 1033-1039.
12. Perdereau C, Godat E, Maurel MC, Hazouard E, Diot E, et al. (2006) Cysteine cathepsins in human silicotic bronchoalveolar lavage fluids. Biochim Biophys Acta 1762: 351-356.
13. Serveau-Avesque C, Martino MF, Herve-Grepinet V, Hazouard E, Gauthier F, et al. (2006) Active cathepsins B, H, K, L and S in human inflammatory bronchoalveolar lavage fluids. Biol Cell 98: 15-22.
14. Kasabova M, Saidi A, Naudin C, Sage J, Lecaille F, et al. (2011) Cysteine Cathepsins: Markers and Therapy Targets in Lung Disorders. Clinic Rev Bone Miner Metab 9: 148-161.
15. May TB, Shinabarger D, Maharaj R, Kato J, Chu L, et al. (1991) Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients. Clin Microbiol Rev 4: 191-206.
16. Quinn DJ, Weldon S, Taggart CC, (2010) Antiproteases as therapeutics to target inflammation in cystic fibrosis. Open Respir Med J 4: 20-31.
17. Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB Jr, et al. (2003) Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 171: 931-937.
18. Rogan MP, Taggart CC, Greene CM, Murphy PG, O'Neill SJ, et al. (2004) Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J Infect Dis 190: 1245-1253.
19. Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, et al. (2001) Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 276: 33345-33352.
20. Martin SL, Moffitt KL, McDowell A, Greenan C, Bright-Thomas RJ, et al. (2010) Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol 45: 860-868.
21. Grasemann H, (2010) Do the cysteine proteinases cathepsin B and S contribute to cystic fibrosis lung disease? Pediatr Pulmonol 45: 845-846.
22. Lalmanach G, Mayer R, Serveau C, Scharfstein J, Gauthier F, (1996) Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi. Biochem J 318 (Pt 2): 395-399.
23. Gilligan PH, Kiska DL, Appleman MD, (2006) Cystic fibrosis microbiology; In: Appleman MD, editors. Coordinating ed., Appleman M.D Washington, D.C. ASM Press.
24. Lalmanach G, Hoebeke J, Moreau T, Ferrer-Di Martino M, Gauthier F, (1992) An immunochemical approach to investigating the mechanism of inhibition of cysteine proteinases by members of the cystatin superfamily. J Immunol Methods 149: 197-205.
25. Florent I, Lecaille F, Montagne JJ, Gauthier F, Schrevel J, et al. (2005) Labelling of four distinct trophozoite falcipains of Plasmodium falciparum by a cystatin-derived probe. Biol Chem 386: 401-406.
26. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, et al. (1982) L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 201: 189-198.
27. Bromme D, Bonneau PR, Lachance P, Wiederanders B, Kirschke H, et al. (1993) Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme. J Biol Chem 268: 4832-4838.
28. Assfalg-Machleidt I, Billing A, Frohlich D, Nast-Kolb D, Joka T, et al. (1992) The role of the kininogens as cysteine proteinase inhibitors in local and systemic inflammation. Agents Actions Suppl 38: 312-321.
29. Buttle DJ, Burnett D, Abrahamson M, (1990) Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest 50: 509-516.
30. Lalmanach G, Naudin C, Lecaille F, Fritz H, (2010) Kininogens: More than cysteine protease inhibitors and kinin precursors. Biochimie 92: 1568-1579.
31. Naudin C, Lecaille F, Chowdhury S, Krupa JC, Purisima E, et al. (2010) The occluding loop of cathepsin B prevents its effective inhibition by human kininogens. J Mol Biol 400: 1022-1035.
32. Godat E, Herve-Grvepinet V, Veillard F, Lecaille F, Belghazi M, et al. (2008) Regulation of cathepsin K activity by hydrogen peroxide. Biol Chem 389: 1123-1126.
33. Herve-Grepinet V, Veillard F, Godat E, Heuze-Vourc'h N, Lecaille F, et al. (2008) Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide. FEBS Lett 582: 1307-1312.
34. Owen CA, (2005) Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 373-385.
35. Korkmaz B, Attucci S, Moreau T, Godat E, Juliano L, et al. (2004) Design and use of highly specific substrates of neutrophil elastase and proteinase 3. Am J Respir Cell Mol Biol 30: 801-807.
36. Korkmaz B, Horwitz MS, Jenne DE, Gauthier F, (2010) Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev 62: 726-759.
37. Gettins PG, (2002) Serpin structure, mechanism, and function. Chem Rev 102: 4751-4804.
38. Potempa J, Korzus E, Travis J, (1994) The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 269: 15957-15960.
39. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, et al. (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276: 33293-33296.
40. Mach L, Mort JS, Glossl J, (1994) Noncovalent complexes between the lysosomal proteinase cathepsin B and its propeptide account for stable, extracellular, high molecular mass forms of the enzyme. J Biol Chem 269: 13036-13040.
41. Majerle A, Jerala R, (2003) Protein inhibitors form complexes with procathepsin L and augment cleavage of the propeptide. Arch Biochem Biophys 417: 53-58.
42. Wiederanders B, (2003) Structure-function relationships in class CA1 cysteine peptidase propeptides. Acta Biochim Pol 50: 691-713.
43. Buttle DJ, Abrahamson M, Burnett D, Mort JS, Barrett AJ, et al. (1991) Human sputum cathepsin B degrades proteoglycan, is inhibited by alpha 2-macroglobulin and is modulated by neutrophil elastase cleavage of cathepsin B precursor and cystatin C. Biochem J 276: 325-331.
44. Taggart CC, Greene CM, Carroll TP, O'Neill SJ, McElvaney NG, (2005) Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease. Am J Respir Crit Care Med 171: 1070-1076.